#Gilead Sciences

The triple-drug regimen comes in a once-daily single tablet.

Maviret and Vosevi were highly effective and well tolerated in clinical trials.

The fixed-dose combination tablet sofosbuvir/velpatasvir/voxilaprevir provides a good alternative to those who have failed treatment.

Highlights from research presented at the 52nd International Liver Congress in Amsterdam

In an analysis of the investigational treatment, cure rates were very high for those without cirrhosis after both 8 and 12 weeks of therapy.

However, eight weeks of sofosbuvir/velpatasvir/voxilaprevir worked as well as 12 weeks of Epclusa for those with genotype 3 and cirrhosis.

A small proof-of-concept study of GS-0976 inhibited de novo lipogenesis (DNL) and reduced liver fat and stiffness.

Merck has long argued that Gilead infringed on a patent-protected biotech invention as the basis for its next-generation hepatitis C cures.

Here are the stories and blogs with the most shares across social media this year.

The triple-drug combo would be the first once-daily, single-tablet regimen for those with all genotypes who’ve failed a previous treatment.

Gilead has tested the addition of the investigational voxilaprevir to its already approved Epclusa (sofosbuvir/velpatasvir).

The updated version of Viread is safer for bones and kidneys.

This U.S. military veteran applied for a routine life insurance policy and got more than he bargained for with a hep C diagnosis.